MedTrace Logo

A Novel Individualized Connectome-guided Approach for Precision Intermittent Theta Burst Stimulation for Depression

NCT06385223 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2024-08-01

No results posted yet for this study

Summary

The Investigators propose to carry out a randomized, double-blind trial to compare the clinical efficacy of an individualized connectome-guided accelerated iTBS vs an anatomically-guided (Beam F3) accelerated iTBS. The study team will recruit both inpatients and outpatients who had been referred for TMS for the treatment of depression.

Conditions

Interventions

DEVICE

Beam F3 targeted accelerated iTBS

Magpro X100, Axilium Cobot, Localite camera

DEVICE

Individualized connectome-guided accelerated iTBS

Magpro X100, Axilium Cobot, Localite camera

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-01
Primary Completion
2026-07-01
Completion
2026-12-31

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06385223 on ClinicalTrials.gov